Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.39 |
| ▸ | OTC | P00480 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.36 |
| ▸ | NPY4R | P50391 | 7/20 | 0.36 |
| ▸ | NPY1R | P25929 | 5/20 | 0.36 |
| ▸ | NPY2R | P49146 | 4/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.36 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.34 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.34 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 3/20 | 0.33 |
| ▸ | NOS3 | P29474 | 2/20 | 0.33 |
| ▸ | NOS2 | P35228 | 2/20 | 0.33 |
| ▸ | RRM1 | P23921 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arginine SCHEMBL8911016 | 0.98 | DPP7 (0.38) | DPP7OTCALOX15MEN1CYP1A2 | |
| Arginine SCHEMBL4273378 | 0.98 | DPP7 (0.40) | DPP7OTCALOX15MEN1CYP1A2 | |
| Arginine SCHEMBL16194704 | 0.96 | DPP7 (0.39) | DPP7OTCALOX15MEN1CYP1A2 | |
| Arginine SCHEMBL7713117 | 0.96 | DPP7 (0.39) | DPP7OTCALOX15MEN1CYP1A2 | |
| Arginine SCHEMBL5653610 | 0.96 | DPP7 (0.39) | DPP7OTCALOX15MEN1CYP1A2 | |
| Arginine SCHEMBL6711066 | 0.96 | DPP7 (0.39) | DPP7OTCALOX15MEN1CYP1A2 | |
| Arginine SCHEMBL3749742 | 0.96 | DPP7 (0.39) | DPP7OTCALOX15MEN1CYP1A2 | |
| Arginine SCHEMBL1766115 | 0.96 | DPP7 (0.39) | DPP7OTCALOX15MEN1CYP1A2 | |
| Arginine SCHEMBL21808680 | 0.96 | DPP7 (0.39) | DPP7OTCALOX15MEN1CYP1A2 | |
| Arginine SCHEMBL7154973 | 0.96 | DPP7 (0.39) | DPP7OTCALOX15MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170008802-A1 | HYDROGEN SULFIDE SCAVENGER | INNOPHOS, INC. (US) | 2017-01-12 | — | — | US | claimed |
| EP-3099747-A1 | HYDROGEN SULFIDE SCAVENGER | Innophos, Inc. (US) | 2016-12-07 | — | — | EP | claimed |
| US-20150218342-A1 | HYDROGEN SULFIDE SCAVENGER | INNOPHOS, INC. (US) | 2015-08-06 | — | — | US | claimed |
| WO-2015116864-A1 | HYDROGEN SULFIDE SCAVENGER | INNOPHOS, INC. (US) | 2015-08-06 | — | — | WO | claimed |
| US-20080114065-A1 | Methods for the treatment of HIV-1 related fat maldistribution, fasting hyperlipidemia and modification of adipocyte physiology | BIONEXUS, LTD. | 2008-05-15 | — | — | US | claimed |
| US-20050233944-A1 | Arginine compositions for coordinate modification of multiple cardiovascular risk factors | BABISH JOHN G | 2005-10-20 | — | — | US | claimed |
| US-20040106591-A1 | Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia | BIONEXUS, LTD. | 2004-06-03 | — | — | US | claimed |
| US-20040005368-A1 | Novel approach to weight loss comprising a modified protein composition that regulates blood sugar in conjunction with compositions that increase oxygen uptake and suppress appetite | MANN MORRIS (US) | 2004-01-08 | — | — | US | claimed |
| US-20030211172-A1 | Composition and method for substantially reducing the deleterious effects of alcohol on the body | JONES JEREMY PARK (US) | 2003-11-13 | — | — | US | claimed |
| US-20030054978-A1 | Arginine compositions for coordinate modification of multiple cardiovascular risk factors | METAPROTEOMICS, LLC | 2003-03-20 | — | — | US | claimed |
| WO-2003020260-A1 | ARGININE COMPOSITIONS FOR COORDINATE MODIFICATION OF MULTIPLE CARDIOVASCULAR RISK FACTORS | METAPROTEOMICS, LLC (US) | 2003-03-13 | — | — | WO | claimed |
| US-6436946-B1 | ENHANCE CEREBRAL CORTICAL ACTIVITY AND SHORT-TERM MEMORY, SUPPRESS APPETITE, REDUCE HAIR LOSS; CAFFEINE, THEOPHYLLINE, AND COGNITIVE COFACTOR: NEUROTRANSMITTER PRECURSORS, CEREBRAL VASODILATORS, NOOTROPIC HERBS, AND AMINO ACIDS | MANN MORRIS A (US) | 2002-08-20 | — | — | US | claimed |
| US-10066079-B2 | Hydrogen sulfide scavenger | INNOPHOS, INC. (US) | 2018-09-04 | — | — | US | disclosed |
| US-20170306129-A1 | HYDROGEN SULFIDE SCAVENGER | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS NOTES COLLATERAL AGENT | 2017-10-26 | — | — | US | disclosed |
| US-20170015811-A1 | HYDROGEN SULFIDE SCAVENGER | INNOPHOS INC. (US) | 2017-01-19 | — | — | US | disclosed |
| US-20170008802-A1 | HYDROGEN SULFIDE SCAVENGER | INNOPHOS, INC. (US) | 2017-01-12 | — | — | US | disclosed |
| US-20040005368-A1 | Novel approach to weight loss comprising a modified protein composition that regulates blood sugar in conjunction with compositions that increase oxygen uptake and suppress appetite | MANN MORRIS (US) | 2004-01-08 | — | — | US | disclosed |
| US-6579866-B2 | Composition for modulating nutrient partitioning in a human | MCCLEARY LARRY (US) | 2003-06-17 | — | — | US | disclosed |
| US-20020132219-A1 | Composition and method for modulating nutrient partitioning | MCCLEARY LARRY (US) | 2002-09-19 | — | — | US | disclosed |
| US-5665385-A | Dietary metal supplements | SOUND NUTRITION, INC. (US) | 1997-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040005368-A1 | Novel approach to weight loss comprising a modified protein composition that regulates blood sugar in conjunction with compositions that increase oxygen uptake and suppress appetite | FABP4, FABP1, FABP6 | DPP7 1664/4885OTC 787/4885ALOX15 2810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.